UNSPSC 51385005: Zomepirac sodium anhydrous

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C15H13ClNO3.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DA5B6IWF46, chemically known as 1h-pyrrole-2-acetic acid, 5-(4-chlorobenzoyl)-1,4-dimethyl-, sodium salt (1:1), but more generally known as zomepirac sodium anhydrous, which bears US NIH Compound Identifier 47290. European Medicines Agency schedules zomepirac sodium anhydrous or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00185MIG.

Most nations, for tariff purposes, schedule zomepirac sodium anhydrous under HS 29339990. SMILES: CC1CC(N(C1C(=O)C2CCC(CC2)CL)C)CC(=O)[O-].[NA+].

UNSPSC 51385005 Zomepirac sodium anhydrous is a Commodity code for a nonsteroidal anti-inflammatory drug; however, the recent state and local activity posted under this code does not reflect pharmaceutical procurement aligned with the code's nominal scope. The single recent opportunity on record—Seminole County, Florida's IFB60459723LAS—solicits naloxone and drug deactivation systems for community health support, which falls outside the zomepirac sodium anhydrous commodity classification. This mismatch suggests either a tagging error in the county's procurement system or an artifact of how the opportunity was indexed. The code shows minimal relevant recent activity in state and local procurement markets.

Seminole County posted the naloxone and drug deactivation systems opportunity on June 30, 2026, with a response deadline of July 26, 2023 (the date appears inconsistent with the posting date and likely reflects a clerical error in the source record). The county seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. Vendors must provide unit costs for each line item, include all shipping and delivery costs, and comply with drug-free workplace certification, E-Verify requirements, and insurance provisions including workers' compensation and commercial general liability. The contract carries a two-year initial term with an optional one-year renewal and a three-month probationary period. Because this solicitation does not align with the zomepirac sodium anhydrous pharmaceutical classification, the code itself does not surface actionable opportunities for vendors in this product line.